Back to Search Start Over

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults.

Authors :
Friberg H
Gargulak M
Kong A
Lin L
Martinez LJ
Schmidt AC
Paris RM
Jarman RG
Diaz C
Thomas SJ
Moris P
Currier JR
Source :
NPJ vaccines [NPJ Vaccines] 2022 Oct 31; Vol. 7 (1), pp. 132. Date of Electronic Publication: 2022 Oct 31.
Publication Year :
2022

Abstract

The increasing global impact of dengue underscores the need for a dengue virus (DENV) vaccine. We assessed B-cell and T-cell responses following vaccination with four formulations of a tetravalent dengue purified inactivated vaccine (DPIV) in dengue-primed and dengue-naive adults from two studies (NCT01666652, NCT01702857). Frequencies of DPIV-induced memory B cells specific to each DENV serotype remained high up to 12 months post-vaccination, and were higher in the dengue-primed than dengue-naive adults. A subsequent DPIV booster dose induced strong anamnestic B-cell responses. Multifunctional CD4+ T cells (predominantly expressing IL-2) were induced by DPIV, with higher frequencies in dengue-primed adults. DPIV-induced CD4+ T cells also demonstrated in vitro proliferative capacity and antigen-specific production of GM-CSF, IFN-γ, and IL-13. CD8+ T-cell responses were undetectable in dengue-naive adults and low in dengue-primed individuals. B- and T-cell responses persisted up to 12 months post-vaccination in both dengue-primed and dengue-naive adults.<br /> (© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022.)

Details

Language :
English
ISSN :
2059-0105
Volume :
7
Issue :
1
Database :
MEDLINE
Journal :
NPJ vaccines
Publication Type :
Academic Journal
Accession number :
36316335
Full Text :
https://doi.org/10.1038/s41541-022-00537-2